JVM-2

产品说明

细胞系来源

Human Caucasian B-prolymphocytic leukaemia, EBV-transformed

细胞系描述

JVM-2 has been derived from EBV and TPA treated mononuclear cells from a 63 year old female patient with B-prolymphocytic leukaemia. Thirty-three percent of cells were shown to be positive for surface lambda light chain, 37% for IgA, 29% for IgG and 3% for IgM and IgD. In addition, 50% were found to express cytoplasmic IgM and lambda light chain. Expression of the following leukocyte differentiation antigens was found: CD9, CD19, CD20, CD23, CD24, MA6, CD37, CD38, FMC1, FMC7, MHC Class I, FMC16, MHC Class II DR/DP/DQ. The immunoglobulin heavy-and light-chain genes showed the same pattern of rearrangement as in the original prolymphocytes. The cells are lymphoblastoid with large floating aggregates present. The cell line has been eradicated from mycoplasma at ECACC.

应用

Ig expression of neoplastic cells

DNA图谱分析

STR-PCR Data: Amelogenin: X
CSF1PO: 11
D13S317: 11,13
D16S539: 12,13
D5S818: 11,12
D7S820: 10,11
THO1: 6,9
TPOX: 8,11
vWA: 17

培养基

RPMI 1640 +2mM Glutamine + 10% Foetal Bovine Serum (FBS).

传代培养常规

Maintain cultures between 3-9 x 100,000/ml; 5% CO₂; 37℃.

其他说明

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

产品性质